Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Launched by NEBRASKA METHODIST HEALTH SYSTEM · Mar 25, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two medications, Labetalol and Nifedipine, to see which one is better at controlling high blood pressure in women after they give birth. High blood pressure after delivery, known as postpartum hypertension, can lead to serious health issues. The goal of the study is to find out which medication helps reduce the risk of patients needing to return to the hospital or facing other complications related to high blood pressure.
Women who are pregnant and at least 24 weeks along, and who have high blood pressure defined as a reading of 140/90 mmHg or higher on two separate occasions, may be eligible to participate. Participants will be given either Labetalol or Nifedipine, and their blood pressure will be monitored closely. This study is currently seeking women and is open to those who speak English or Spanish. It’s important to note that women with certain heart conditions or asthma may not be able to participate. Overall, this trial aims to help improve the care and outcomes for women dealing with high blood pressure after childbirth.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.
- Exclusion Criteria:
- • History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema
- • Contraindication to either Nifedipine or Labetalol
- • HR \<60 or \>110
- • Native language other than English or Spanish
About Nebraska Methodist Health System
Nebraska Methodist Health System is a leading healthcare organization dedicated to delivering exceptional patient care and advancing medical research through innovative clinical trials. With a strong commitment to evidence-based practices, the health system collaborates with various stakeholders to enhance treatment options and improve health outcomes. Its clinical trial programs are designed to explore new therapies and interventions across a range of medical conditions, ensuring that patients have access to cutting-edge treatments while contributing to the advancement of medical knowledge. Nebraska Methodist Health System fosters a culture of integrity, compassion, and excellence, positioning itself as a trusted partner in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Omaha, Nebraska, United States
Patients applied
Trial Officials
Todd Lovgren, MD
Principal Investigator
Nebraska Methodist Health System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials